Common pain relievers may worsen C. difficile infection

Clostridium difficile, also called C. difficile or C. diff, is a bacterium that causes inflammation of the colon. This health condition commonly affects older adults in hospitals, and it often occurs after the use of antibiotic medications. According to the Centers for Disease Control and Prevention, C. difficile led to almost half a million infections among patients in the United […]

Read more

Drug helps against pain during Sex

The drug Gabapentin might help if women suffer during intercourse chronic pain. By taking they felt less pain during your sexual Desire and satisfaction have increased. Although their sexual function was not completely restored, had the Request of the women after taking Gabapentin in less pain and more sexual. In particular, women with strong pain profited from the treatment. Gabapentin […]

Read more

Opioids Offer Small Improvement in Pain, Physical Function

TUESDAY, Dec. 18, 2018 — Opioid use is associated with small improvements in pain and physical functioning in patients with chronic noncancer pain, according to research published in the Dec. 18 issue of the Journal of the American Medical Association. Jason W. Busse, Ph.D., from McMaster University in Hamilton, Ontario, Canada, and colleagues conducted a systematic review of randomized clinical […]

Read more

Researchers developing nonopioid drug for chronic pain

Researchers from the Virginia Tech School of Neuroscience are teaming with the University of California San Diego and the U.S. National Institutes of Health to develop a drug—now in its earliest stages—that can treat certain types of chronic pain without the addictive consequences of opioids. The drug compound, known as ML351, was discovered by researchers from the NIH, part of […]

Read more

Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients

NEW YORK & INDIANAPOLIS–(BUSINESS WIRE October 23, 2018 )–Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced complete results from a Phase 3 study evaluating the efficacy and safety of subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, in patients with osteoarthritis (OA) pain treated for 16 weeks. The study met all three co-primary efficacy endpoints, demonstrating […]

Read more